Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Open Access
- 1 August 1990
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 86 (2), 385-391
- https://doi.org/10.1172/jci114723
Abstract
Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. Using plasma fibrinopeptide A (FPA) levels as an index of thrombin activity, we compared the ability of thrombin inhibitors to block FPA release mediated by fluid-phase thrombin with their activity against the clot-bound enzyme. Incubation of thrombin with citrated plasma results in concentration-dependent FPA generation, which reaches a plateau within minutes. In contrast, there is progressive FPA generation when fibrin clots are incubated with citrated plasma. Heparin, hirudin, hirudin dodecapeptide (hirugen), and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK) produce concentration-dependent inhibition of FPA release mediated by fluid-phase thrombin. However, heparin is much less effective at inhibiting thrombin bound to fibrin because a 20-fold higher concentration is necessary to block 70% of the activity of the clot-bound enzyme than is required for equivalent inhibition of fluid-phase thrombin (2.0 and 0.1 U/ml, respectively). In contrast, hirugen and PPACK are equally effective inhibitors of fluid- and solid-phase thrombin, while hirudin is only 50% as effective against the clot-bound enzyme. None of the inhibitors displace bound 125I-labeled thrombin from the clot. These studies indicate that (a) clot-bound thrombin is relatively protected from inhibition by heparin, possibly because the heparin binding site on thrombin is inaccessible when the enzyme is bound to fibrin, and (b) clot-bound thrombin is susceptible to inactivation by antithrombin III-independent inhibitors because the sites of their interaction are not masked by thrombin binding to fibrin. For these reasons, antithrombin III-independent inhibitors may be more effective than heparin in certain clinical settings.This publication has 34 references indexed in Scilit:
- Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.1989
- Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.Proceedings of the National Academy of Sciences of the United States of America, 1989
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Kinetics of the inhibition of thrombin by hirudinBiochemistry, 1986
- SELECTIVE IMMOBILIZATION OF ALPHA-THROMBIN BY SURFACE-BOUND FIBRIN1981
- D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombinThrombosis Research, 1979
- Equilibrium binding of thrombin to plateletsBiochemistry, 1976
- Heparin kinetics in venous thrombosis and pulmonary embolism.Cell Metabolism, 1976
- Specificity of Antisera to Human Fibrinopeptide A Used in Clinical Fibrinopeptide A AssaysThrombosis and Haemostasis, 1976
- Note on the Adsorption of Thrombin on FibrinScience, 1945